NCT05484414View on ClinicalTrials.gov

Safety and Pharmacokinetics of SAD/MAD Oral Doses of SRP-3D (DA)

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

July 16, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

March 28, 2026

Conditions
Pain
Interventions
DRUG

SRP-3D (diethylamide)

SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL

DRUG

Placebo

Matching Placebo for SRP-3D (Diethylamide) Oral Suspension, 100 mg/mL

Trial Locations (1)

33126

Quotient Sciences-Miami, Inc., Miami

All Listed Sponsors
lead

South Rampart Pharma, LLC

INDUSTRY